Your browser doesn't support javascript.
loading
Epidemiological features of immunoglobulin G4-related sclerosing cholangitis in Japan.
Tanaka, Atsushi; Mori, Mitsuru; Kubota, Kensuke; Naitoh, Itaru; Nakazawa, Takahiro; Takikawa, Hajime; Unno, Michiaki; Kamisawa, Terumi; Kawa, Shigeyuki; Okazaki, Kazuichi.
Afiliação
  • Tanaka A; Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.
  • Mori M; Hokkaido Chitose College of Rehabilitation, Chitose, Japan.
  • Kubota K; Department of Endoscopy, Yokohama City University Hospital, Yokohama, Japan.
  • Naitoh I; Department of Gastroenterology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Nakazawa T; Department of Gastroenterology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Takikawa H; Faculty of Medical Technology, Teikyo University, Tokyo, Japan.
  • Unno M; Division of Hepato-Biliary Pancreatic Surgery, Tohoku University Graduate School, of Medicine, Sendai, Japan.
  • Kamisawa T; Department of Internal Medicine, Tokyo Metropolitan, Komagome Hospital, Tokyo, Japan.
  • Kawa S; Department of Internal Medicine, Matsumoto Dental University, Matsumoto, Japan.
  • Okazaki K; The Third Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
J Hepatobiliary Pancreat Sci ; 27(9): 598-603, 2020 Sep.
Article em En | MEDLINE | ID: mdl-32603554
BACKGROUND/PURPOSE: Epidemiological data on immunoglobulin G4-related sclerosing cholangitis (IgG4-SC) are scarce. METHOD: We randomly selected healthcare facilities from a list of all facilities in Japan. The selection rate was determined according to a stratification based on the facility characteristics and scale. We sent questionnaires to the selected facilities enquiring about the number and sex of patients with IgG4-SC in 2018. Among responding facilities, we further inquired about the clinical characteristics of the patients with IgG4-SC. RESULTS: We selected 1180 departments from health centers across Japan. Of them, 532 (45.1%) responded to the questionnaires. The number of reported patients with IgG4-SC was 1045, and the estimated point prevalence was 2.18 (95% confidence interval, 2.13-2.23) per 100 000 population. In addition, we enrolled 1096 patients with IgG4-SC, combining data from previously and newly registered patients. Male patients comprised 79.5% of the population and patients aged 60-80 years had the highest risk for developing the disease. The follow-up period was 5.1 ± 4.0 years and the 5- and 10-year overall survival rates were 95.3% and 89.0%, respectively. CONCLUSIONS: The point prevalence of IgG4-SC was 2.18 per 100 000 population. The epidemiological features were similar to those observed in previous studies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Colangite Esclerosante Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Colangite Esclerosante Idioma: En Ano de publicação: 2020 Tipo de documento: Article